Kidney transplantation with Belzer or Custodiol solution: a randomized prospective study.
OBJECTIVE
The purpose of this study was to compare the Belzer vs Custodiol solutions for cadaveric kidney perfusion in relation to delayed graft function, renal function, acute rejection episodes, and patient and graft survivals.


METHODS
This randomized prospective study included 42 kidneys and 9 simultaneous kidney and pancreas recipients from December 2002 to February 2004, namely 24 in the Custodiol arm and 27 in the Belzer arm. We analyzed delayed graft function frequency, acute rejection episodes (biopsy proven), renal function (creatinine at 1, 6, and 12 months), as well as graft and patient survivals. Categorical and continuous variables were evaluated as appropriate.


RESULTS
We failed to observe a difference in the immunosuppressant drug protocol, cold ischemia time, or mean recipient or donor age. The prevalence of delayed graft function was 63% among the Belzer arm, and 50% among the Custodiol arm (P = NS). The renal function was the same in both arms at 1, 6, and 12 months. The graft survival after 3 months was 94% among the Belzer group (death from sepsis), and 95% among the Custodiol group (nonfunctioning graft). At 1 year, the results were 78% among the Belzer group (4 deaths from cardiovascular or infectious complications and 2 graft losses), and 79% among the Custodiol group (3 deaths, 1 primary nonfunctioning graft, and 1 graft loss; P = NS). After 12 months follow-up, patient survival was 84% among the Belzer group, and 86% among the Custodiol group. In the first year, the incidences of biopsy-proven acute rejection episodes were 37% among the Belzer group, and 33% among the Custodiol group.


CONCLUSIONS
Custodiol solution achieved similar results compared with Belzer solution.
Klaus
F
F
Department of Nephrology, Complexo Hospitalar Santa Casa de Porto Alegre, Porto Alegre, RS, Brazil.
Castro
D B
DB
Bittar
C M
CM
Bittar
A E
AE
Keitel
E
E
Seelig
D C
DC
Goldani
J C
JC
Meinne
M H
MH
Garcia
V D
VD
D000208:Acute Disease; D000241:Adenosine; D000493:Allopurinol; D005260:Female; D005947:Glucose; D005978:Glutathione; D006084:Graft Rejection / Q000453:epidemiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007328:Insulin; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality; D007902:Length of Stay; D008297:Male; D008353:Mannitol; D019188:Organ Preservation Solutions; D016035:Pancreas Transplantation / Q000276:immunology / Q000401:mortality; D011183:Postoperative Complications / Q000453:epidemiology; D011189:Potassium Chloride; D011343:Procaine; D011446:Prospective Studies; D011887:Raffinose; D016019:Survival Analysis
C039984:Bretschneider cardioplegic solution; D007166:Immunosuppressive Agents; D007328:Insulin; D019188:Organ Preservation Solutions; C055206:University of Wisconsin-lactobionate solution; D008353:Mannitol; D011343:Procaine; D000493:Allopurinol; D011189:Potassium Chloride; D005978:Glutathione; D005947:Glucose; D000241:Adenosine; D011887:Raffinose